FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmacology, representing a monolith implant containing (i) analogue of the luteinising hormone releasing-factor (=LH-RH analogue) or a pharmaceutically acceptable salt thereof in an amount of no less than 25% of the composition total weight (ii) polylactid homogenous polymer resistant to degradation caused by gamma-irradiation and/or thermal effects where polylactid polymer resistant to degradation demonstrates decomposition degree less than 1000 Daltons relative to the polymer average molecular weight after gamma-irradiation with a dose equal to 25 - 40 kGy of ionising gamma-radiation and/or where polylactid polymer resistant to degradation demonstrates decomposition degree less than 1000 Daltons relative to the polymer average molecular weight after thermal effect at a temperature of approximately 30°C during a period of at least 24 months where polylactid polymer resistant to degradation has average molecular weight from 4800 to 8600 Daltons.
EFFECT: invention ensures high quality of the implant and enhances safety for patients.
11 cl, 3 ex, 3 tbl, 3 dwg
